Influence of critical parameters of nanosuspension formulation on the permeability of a poorly soluble drug through the skin - A case study

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 1108-1117

  Ghosh, Indrajit ^a,b,c   Michniak Kohn, Bozena ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CELGENE CORPORATION   (United States)

Author keywords

dermal drug delivery; human skin; nanosuspension; permeation rate; porcine skin; vitamin E TPGS

Indexed keywords

IBUPROFEN; NANOPARTICLE; TOCOFERSOLAN;

ARTICLE; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; GEL; HUMAN; HUMAN TISSUE; PARTICLE SIZE; PRIORITY JOURNAL; SKIN PERMEABILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; IBUPROFEN; NANOTECHNOLOGY; PERMEABILITY; SKIN ABSORPTION; SOLUBILITY; THERMODYNAMICS;

EID: 84890154853     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9995-4     Document Type: Article

References (31)

1. Choi JS, Shin SC. Preparation and evaluation of pranoprofen gel for percutaneous administration. Drug Dev Ind Pharm. 2007;33:19-26.
2. Davis AF, Hadgraft J. Supersaturated solutions as topical drug delivery systems. Pharmaceutical Skin Penetration Enhancement. Marcel Dekker. 1993; 243-67.
3. Choi CW, Choi JS, Shin SC. Development of the ambroxol gels for enhanced transdermal delivery ambroxol gels for enhanced transdermal delivery. Drug Dev Ind Pharm. 2008;34:330-5.
4. Song JH, Shin SC. Development of the loratadine gel for enhanced transdermal delivery. Drug Dev Ind Pharm. 2009;5:897-903.
5. Baboota S, Shakeel F, Kohli K. Formulation and evaluation of once-a-day transdermal gels of diclofenac diethylamine. Methods Find Exp Clin Pharmacol. 2006;28:109-14.
6. Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm. 2000;198:229-38.
7. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm. 1999;184:1-6.
8. Pellett MA, Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 2. Piroxicam. Int J Pharm. 1994;111:1-6.
9. Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int J Pharm. 1991;76:1-8.
10. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J, Schaefer H, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1ap cells after transcutaneous application on human skin. J Investig Dermatol. 2006;26:1316-22.
11. Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, et al. Nanoparticles - an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66:159-64.
12. Mishra PR, Shaal LA, Müller RH, Keck CM. Production and characterization of esperetin nanosuspensions dermal delivery. Int J Pharm. 2009;371:182-9.
13. Kobierski S, Ofori-Kwakye K, Müller RH, Keck CM. Resveratrol nanosuspensions for dermal application-production, characterization and physical stability. Pharmazie. 2009;64:741-7.
14. Juhnke M, Märtin D, John E. Generation of wear during the production of drug nanosuspensions by wet media milling. Eur J Pharm Biopharm. 2012;81:214-22.
15. Ghosh I, Michniak-Kohn B. A comparative study of Vitamin E TPGS/HPMC supersaturated system and other solubilizer/polymer combinations to enhance the permeability of a poorly soluble drug through the skin. Drug Dev Ind Pharm. 2012; 1-9, Early Online.
16. Garcia MTJ, Silva CHTP, Oliveira DCR, Braga ECA, Thomazini JA, Bentley MVLB. Transdermal delivery of ketoprofen: the influence of drug- dioleylphosphatidylcholine interactions. Pharm Res. 2006;8:1776-85.
17. Berba J, Goranson S, Langle J, Banakar UV. In vitro release of selected non-steroidal anti-inflammatory analgesic from reservoir type transdermal formulations. Drug Dev Ind Pharm. 1991;146:255-62.
18. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409:260-8.
19. Keck CM. Particle size analysis of nanoparticles: improved analysis method. Int J Pharm. 2012;390:3-12.
20. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: influence of polymers. Int J Pharm. 1999;93:231-7.
21. George M, Ghosh I. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur J Pharm Sci. 2013;48:142-52.
22. Van Eerdenburgh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64-75.
23. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-44.
24. Gao G, Li Z, Sun M, Li H, Guo C, Cui J, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm. 2010;36:1225-34.
25. Grant DJW, Brittain HG. Solubility of pharmaceutical solids. In: Brittain HG, editor Physical Characterization of Pharmaceutical Solids. Marcel Dekker. 1995; 321-86.
26. Li S, Pollock-Dove C, Dong LC, Chen J, Creasey AA, Dai WG. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study. Mol Pharm. 2012;9:1100-8.
27. Ghosh I, Schenck D, Bose S, Liu F, and Motto M. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology - A QbD perspective. Pharm Dev Technol. 2012; Early Online: 1-11.
28. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm. 2000;193:231-7.
29. Mitria K, Shegokara R, Gohlac S, Anselmib C, Müllera RH. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm. 2011;420:141-6.
30. Müller RH, Shegokar RGS, Keck CM. Nanocrystals: production, cellular drug delivery, current and future products. Fundam Biomed Technol. 2011;5:411-32.
31. Ghosh I, Michniak-Kohn B. Design and characterization of submicron formulation for a poorly soluble drug: the effect of vitamin E TPGS and other solubilizers on skin permeability enhancement. Int J Pharm. 2012;434:90-8.